NYSE:PKI

Stock Analysis Report

Executive Summary

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide.

Snowflake

Fundamentals

Acceptable track record with moderate growth potential.


Similar Companies

Share Price & News

How has PerkinElmer's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.0%

PKI

-0.8%

US Life Sciences

1.3%

US Market


1 Year Return

-4.4%

PKI

13.1%

US Life Sciences

5.9%

US Market

Return vs Industry: PKI underperformed the US Life Sciences industry which returned 13.1% over the past year.

Return vs Market: PKI underperformed the US Market which returned 5.9% over the past year.


Shareholder returns

PKIIndustryMarket
7 Day-3.0%-0.8%1.3%
30 Day-5.6%-4.2%-1.9%
90 Day-14.1%-3.6%-1.8%
1 Year-4.1%-4.4%13.3%13.1%8.3%5.9%
3 Year59.6%58.0%79.3%77.9%45.6%36.2%
5 Year108.7%104.3%123.9%113.7%66.1%47.9%

Price Volatility Vs. Market

How volatile is PerkinElmer's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PerkinElmer undervalued compared to its fair value and its price relative to the market?

36.06x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: PKI ($81.86) is trading above our estimate of fair value ($79.39)

Significantly Undervalued: PKI is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PKI is poor value based on its PE Ratio (36.1x) compared to the Life Sciences industry average (32.2x).

PE vs Market: PKI is poor value based on its PE Ratio (36.1x) compared to the US market (17.5x).


Price to Earnings Growth Ratio

Low PEG Ratio: PKI is poor value based on its PEG Ratio (1.7x)


Price to Book Ratio

PB vs Industry: PKI is good value based on its PB Ratio (3.4x) compared to the US Life Sciences industry average (4.5x).


Next Steps

Future Growth

How is PerkinElmer forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

21.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PKI's forecast earnings growth (21.1% per year) is above the savings rate (2.7%).

Earnings vs Market: PKI's earnings (21.1% per year) are forecast to grow faster than the US market (14.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PKI's revenue (7% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: PKI's revenue (7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: PKI's Return on Equity is forecast to be low in 3 years time (15.4%).


Next Steps

Past Performance

How has PerkinElmer performed over the past 5 years?

3.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PKI's earnings have grown by 3.7% per year over the past 5 years.

Accelerating Growth: PKI's earnings growth over the past year (68.9%) exceeds its 5-year average (3.7% per year).

Earnings vs Industry: PKI earnings growth over the past year (68.9%) exceeded the Life Sciences industry 45%.


Return on Equity

High ROE: PKI's Return on Equity (9.3%) is considered low.


Return on Assets

ROA vs Industry: PKI's Return on Assets is below or equal to the Life Sciences industry average last year.


Return on Capital Employed

ROCE Improving: PKI's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is PerkinElmer's financial position?


Financial Position Analysis

Short Term Liabilities: PKI's short term assets ($1.3B) exceeds its short term liabilities ($706.8M)

Long Term Liabilities: PKI's short term assets (1.3B) do not cover its long term liabilities (3.0B)


Debt to Equity History and Analysis

Debt Level: PKI's debt to equity ratio (78%) is considered high

Reducing Debt: PKI's debt to equity ratio has increased from 41.6% to 78% over the past 5 years.

Debt Coverage: PKI's debt is not well covered by operating cash flow (13.9%).

Interest Coverage: PKI's interest payments on its debt are well covered by EBIT (5.9x coverage).


Balance Sheet

Inventory Level: PKI has a low level of unsold assets or inventory.

Debt Coverage by Assets: PKI's debt is not covered by short term assets (assets are 0.6x debt).


Next Steps

Dividend

What is PerkinElmer's current dividend yield, its reliability and sustainability?

0.34%

Current Dividend Yield


Upcoming Dividend Payment

Purchase PerkinElmer before the 'Buy Limit' to receive their next dividend payment.


Dividend Yield vs Market

company0.3%marketbottom25%1.5%markettop25%3.8%industryaverage0.4%forecastin3Years0.3%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: PKI's dividend (0.34%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.47%).

High Dividend: PKI's dividend (0.34%) is low compared to the top 25% of dividend payers in the US market (3.77%).

Stable Dividend: PKI is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: PKI is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: PKI is not paying a notable dividend for .


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PKI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of PerkinElmer's salary, the management and board of directors tenure and is there insider trading?

3.5yrs

Average management tenure


CEO

Rob Friel (63yo)

11.7yrs

Tenure

US$13,961,376

Compensation

Mr. Robert F. Friel, also known as Rob, has been the Chairman of PerkinElmer Inc. since April 29, 2009 and also its Executive Director since January 1, 2006. He has been the Chairman of PerkinElmer LAS (Ge ...


CEO Compensation Analysis

Compensation vs. Market: Rob's total compensation ($USD13.96M) is about average for companies of similar size in the US market ($USD6.81M).

Compensation vs Earnings: Rob's compensation has increased by more than 20% in the past year.


Management Age and Tenure

3.5yrs

Average Tenure

50.5yo

Average Age

Experienced Management: PKI's management team is considered experienced (3.5 years average tenure).


Board Age and Tenure

4.0yrs

Average Tenure

61yo

Average Age

Experienced Board: PKI's board of directors are considered experienced (4 years average tenure).


Insider Trading

Insider Buying: PKI insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$165,12003 Sep 19
Alexis Michas
EntityIndividual
Role
Lead Director
Lead Director
Shares2,000
Max PriceUS$82.56
SellUS$148,27407 Feb 19
Nicholas Lopardo
EntityIndividual
Shares1,600
Max PriceUS$92.67
SellUS$454,75004 Dec 18
Alexis Michas
EntityIndividual
Role
Lead Director
Lead Director
Shares5,000
Max PriceUS$90.95
SellUS$174,16003 Dec 18
Nicholas Lopardo
EntityIndividual
Shares2,000
Max PriceUS$87.08
SellUS$816,40014 Nov 18
Patrick Sullivan
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares10,000
Max PriceUS$81.64
SellUS$184,45507 Nov 18
Pascale Witz
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares2,206
Max PriceUS$83.62
SellUS$164,24406 Nov 18
Nicholas Lopardo
EntityIndividual
Shares2,000
Max PriceUS$82.12

Ownership Breakdown


Management Team

  • Rob Friel (63yo)

    Chairman & CEO

    • Tenure: 11.7yrs
    • Compensation: US$13.96m
  • Dave Francisco

    CFO of Human Health & Corporate Treasurer

    • Tenure: 0yrs
  • Tajinder Vohra (53yo)

    Senior Vice President of Global Operations

    • Tenure: 1.7yrs
  • Joel Goldberg (50yo)

    Senior VP of Administration

    • Tenure: 11.3yrs
    • Compensation: US$3.08m
  • Andrew Okun (49yo)

    VP & Chief Accounting Officer

    • Tenure: 8.5yrs
  • Jamey Mock (42yo)

    Senior VP & CFO

    • Tenure: 1.4yrs
    • Compensation: US$4.27m
  • Daniel Tereau (51yo)

    Senior Vice President of Strategy & Business Development

    • Tenure: 3.8yrs
  • Deborah Butters (49yo)

    Senior VP & Chief Human Resources Officer

    • Tenure: 3.3yrs
  • Prahlad Singh (54yo)

    President

    • Tenure: 0.2yrs
    • Compensation: US$2.06m
  • Bryan Kipp

    Vice President of Investor Relations

    • Tenure: 0yrs

Board Members

  • Alexis Michas (61yo)

    Lead Director

    • Tenure: 0yrs
    • Compensation: US$337.01k
  • Pat Sullivan (67yo)

    Independent Director

    • Tenure: 11.7yrs
    • Compensation: US$268.76k
  • Sylvie Grégoire (58yo)

    Independent Director

    • Tenure: 4.7yrs
    • Compensation: US$265.01k
  • Rob Friel (63yo)

    Chairman & CEO

    • Tenure: 11.7yrs
    • Compensation: US$13.96m
  • Peter Barrett (66yo)

    Independent Director

    • Tenure: 7.7yrs
    • Compensation: US$276.26k
  • Frank Witney (65yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: US$265.01k
  • Sam Chapin (61yo)

    Independent Director

    • Tenure: 3yrs
    • Compensation: US$290.01k
  • Pascale Witz (52yo)

    Independent Director

    • Tenure: 2yrs
    • Compensation: US$265.01k
  • Prahlad Singh (54yo)

    President

    • Tenure: 0.2yrs
    • Compensation: US$2.06m

Company Information

PerkinElmer, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PerkinElmer, Inc.
  • Ticker: PKI
  • Exchange: NYSE
  • Founded: 1937
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$9.093b
  • Shares outstanding: 111.08m
  • Website: https://www.perkinelmer.com

Number of Employees


Location

  • PerkinElmer, Inc.
  • 940 Winter Street
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PKINYSE (New York Stock Exchange)YesCommon StockUSUSDJan 1968
PKNDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1968
0KHELSE (London Stock Exchange)YesCommon StockGBUSDJan 1968
PKI *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 1968

Biography

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solution ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 23:41
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.